p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment.
p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment.
复制标题
DOI：
10.4172/2168-9652.1000e153
复制
发表时间：
2016-10
期刊：
影响因子：
--
通讯作者：
A. Arbab;Meenu Jain;B. R. Achyut
中科院分区：
文献类型：
--
作者：
A. Arbab;Meenu Jain;B. R. Achyut
There has been a trend of use of conventional or non-conventional therapies against cancer such as targeting “king pin” tumor cells itself, targeting tumor vasculature lined by endothelial cells, targeting tumor associated macrophages and recently, targeting inhibitory signals on T cells through immunotherapies in tumor microenvironment (TME). However, most of the cases have witnessed therapy resistance flowing a short-term or transient benefit. Despite of several failures in clinical trials targeting tumors and their microenvironments, our understanding is improving every day. It is evident that mutations in tumor cell compartment play a critical role in cancer development as well as therapy resistance. Here, we have discussed studies representing therapy resistance, through p53 as a model mutation and glioblastoma (GBM) as a model tumor.
